Researchers compared the effectiveness of sacubitril/valsartan with valsartan alone in patients with severe heart failure and a recent history of New York Heart Association class IV symptoms. The double-blind randomized clinical trial Involved 335 patients with severe heart failure. Patients were randomized to either Sacubitril/valsartan (target dose of 200 mg twice daily) or Valsartan alone (target dose of 160 mg twice daily). Results showed no improvement in the number of days alive, out of hospital, and free from heart failure events with sacubitril/valsartan compared to valsartan. Researchers concluded that in patients with advanced heart failure with reduced ejection fraction, there was no significant difference in the effect of sacubitril/valsartan and valsartan alone on NT-proBNP levels.

Reference: Mann DL, Givertz MM, Vader JM, et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA Cardiol. 2022;7(1):17–25. doi:10.1001/jamacardio.2021.4567.